Although this results in relatively stable results across the whole risk spectrum, results can also be misleading: A statistically highly significant relative risk reduction of 50% may turn out to be clinically irrelevant, if the baseline risk is very low for an event in the placebo group.
← all excerpts
Meta-analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes.
1
—
—